Company AZ, overall value, stage of development at signature, type of component of the agreement, specific therapeutic target and type of technology

DUBLIN, June 16, 2021 / PRNewswire / – The report “Global Hematology Partnering 2010-2021: Deal Trends, Players and Financials” has been added to offer.

The Global Hematology Partnering 2010-2021 report provides full access to available agreements and contractual documents for over 550 hematology agreements.

Most of the transactions included in the report occur when a licensee obtains a right or option right to a product or technology from a licensor. More often nowadays, these agreements tend to be multi-component, comprising both an element of collaborative R&D and an element of commercialization of results.

The report introduces readers to comprehensive hematological disease agreement trends, key players, and major agreement values, providing an understanding of how, why, and under what conditions companies are currently entering into hematology agreements.

The report presents the values ​​of financial agreement terms for hematology agreements, if applicable, by aggregate values, upfront payments, milestones and royalties allowing readers to analyze and compare the value of open agreements.

In addition, a complete appendix is ​​provided with each report of all hematology partnership agreements signed and announced since 2010. The appendices are organized by company from A to Z, stage of development at signature, type of agreement (collaborative R&D , co-promotion, license, etc.) and type of technology. Each transaction title is linked via a web link to an online version of the transaction record and, if applicable, the contractual document, providing easy access to each contractual document on demand.

The report includes offers for the following indications: agranulocytosis, v, hemolytic, iron deficiency, blood substitute, disseminated intravascular coagulation (DIC), hemophilia, immune thrombocytopenic purpura, neutropenia, polycythemia, thalassemia, thrombocytopenia, vitamin K deficiency, disease Von-Willebrand, as well as other haematological indications.

In conclusion, this report provides everything a potential negotiator needs to know about partnering in the research, development and commercialization of hematology technologies and products.

Scope of the report

The 2010-2021 Global Hematology Partnership includes:

  • Trends in hematology transactions in the biopharmaceutical industry since 2010
  • Analysis of the structure of the hematology offer
  • Access to title, advance, milestone and royalty data
  • Access to hundreds of contractual documents in hematology
  • Full access to more than 550 business files in hematology
  • The best hematology offers by value since 2010
  • The most active hematology negotiators since 2010

The offers and contracts available are listed by:

  • Title value
  • Initial payment value
  • Royalty rate value
  • Stage of development at signing
  • Component type of the agreement
  • Type of technology
  • Specific therapeutic indication

The analysis of actual contractual agreements makes it possible to assess the following elements:

  • What are the specific rights granted or opted out?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the transaction?
  • How are sales and payments audited?
  • How long is the agreement?
  • How are the key terms of the agreement defined?
  • How are IPRs managed and held?
  • Who is responsible for marketing?
  • Who is responsible for development, sourcing and manufacturing?
  • How is confidentiality and publication managed?
  • How to resolve disputes?
  • Under what conditions can the deal be terminated?
  • What happens in the event of a change of owner?
  • What sub-licensing and subcontracting arrangements have been agreed?
  • What standard clauses does the company insist on?
  • Which standard clauses seem to differ from one partner to another or from one type of agreement to another?
  • What jurisdiction does the company insist on for the law of agreements?

Main topics covered:


Chapter 1 Introduction

Chapter 2 – Trends in hematology negotiations
2.1. introduction
2.2. A partnership in hematology over the years
2.3. Hematology partnership by type of agreement
2.4. Hematology partnerships by sector of activity
2.5. Partnership in hematology by stage of development
2.6. Hematology partnership by type of technology
2.7. Hematology partnership by therapeutic indication

Chapter 3 – Financial conditions of the hematology partnership
3.1. introduction
3.2. Financial terms disclosed for the hematology partnership
3.3. Key values ​​of the hematology partnership
3.4. Upfront payments of the hematology agreement
3.5. Milestone payments of the hematology agreement
3.6. Hematology royalty rate

Chapter 4 – Main contracts and negotiators in hematology
4.1. introduction
4.2. The most active in the hematology partnership
4.3. List of the most active dealmakers in hematology
4.4. Best Hematology Deals by Value

Chapter 5 – Directory of hematology contractual documents
5.1. introduction
5.2. Partnership agreements in hematology when the contractual document is available

Chapter 6 – The hematology deal by therapeutic target
6.1. introduction
6.2. Offers by therapeutic target Hematology


Appendix 1 – Directory of hematology offers by company AZ 2010 to 2021
Appendix 2 – Directory of Hematology deals by type of deal 2010 to 2021
Appendix 3 – Directory of hematology offers by stage of development 2010 to 2021
Appendix 4 – Directory of hematology offers by type of technology 2010 to 2021

For more information on this report, visit

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

Source link

About Molly Brown

Check Also

A popular Facebook post earlier this year cast doubt on the COVID-19 vaccine

Facebook withheld a first quarter popular content report for fear of backlash, The New York …